“…[22][23][24][25][26][27][28][29][30][31][32] Some of the reasons for these discrepancies may be ethnic variations, completeness of eradication, stage of the disease when treatment was initiated, and the short follow-up period (in most studies the follow-up period did not exceed 1 year). 17,23,27,28,30,32 We developed a monoclonal antibody (mAb), Das-1 (formerly known as 7E 12 H 12 , immunoglobulin [Ig]M isotype), that specifically reacts with colonic epithelium 33 (both goblet and nongoblet absorptive cells), but not with enterocytes (including goblet cells) from jejunum or ileum and normal epithelium from the stomach and esophagus. 33,34 However, mAb Das-1 reacts sensitively (95%) and specifically (100%) to Barrett's epithelium, a preneoplastic condition of the esophagus, and adenocarcinoma of the esophagus.…”